Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
A secondary analysis of the COORDINATE-Diabetes trial found that up to one-third of patients with Type 2 diabetes and atherosclerotic cardiovascular disease stopped their SGLT-2i or GLP-1RA within 12 months, with cost and side effects among the cited reasons. PICO summary and expert commentary.
A secondary analysis of the VA NEPHRON-D cohort found that higher baseline urinary EGF and uromodulin were independently associated with a lower risk of diabetic kidney disease progression. PICO summary and expert commentary.
A FOURIER subgroup analysis of 197 participants asks whether evolocumab cuts cardiovascular events in type 1 diabetes with established ASCVD. PICO summary and expert commentary.
A prespecified STRIDE subgroup analysis examined whether once-weekly semaglutide 1.0 mg improves walking distance consistently across diabetes characteristics in 792 adults with symptomatic PAD and type 2 diabetes. PICO summary and expert commentary.
A randomized crossover trial found the cardiac output response to 3-hydroxybutyrate was blunted by roughly 80% in type 1 diabetes, with no gain in systolic function and reduced ventricular work efficiency. PICO summary and expert commentary.
A post-hoc EXSCEL analysis testing whether baseline ejection fraction modifies the effect of once-weekly exenatide on heart failure hospitalisation in type 2 diabetes. PICO summary and expert commentary.
Exploratory analysis of AMPLITUDE-O finds baseline FIB-4 score is not associated with cardiovascular outcomes and does not modify efpeglenatide's effect in high-risk type 2 diabetes. PICO summary and expert commentary.
A double-blind RCT testing whether the Omentin-1 Val109Asp genotype modifies vitamin D's effects on HDL-C, insulin resistance and abdominal obesity in prediabetic women. PICO summary and expert commentary.
A prediction-model study finds a nomogram of preoperative HDL-C and visceral fat forecasts visceral fat loss after sleeve gastrectomy (AUC 0.88). PICO summary and commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
